These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2124935)

  • 1. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator.
    Gardell SJ; Hare TR; Bergum PW; Cuca GC; O'Neill-Palladino L; Zavodny SM
    Blood; 1990 Dec; 76(12):2560-4. PubMed ID: 2124935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural features mediating fibrin selectivity of vampire bat plasminogen activators.
    Bringmann P; Gruber D; Liese A; Toschi L; Krätzchmar J; Schleuning WD; Donner P
    J Biol Chem; 1995 Oct; 270(43):25596-603. PubMed ID: 7592732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the interactions of plasminogen and tissue and vampire bat plasminogen activators with fibrinogen, fibrin, and the complex of D-dimer noncovalently linked to fragment E.
    Stewart RJ; Fredenburgh JC; Weitz JI
    J Biol Chem; 1998 Jul; 273(29):18292-9. PubMed ID: 9660794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. A kinetic analysis.
    Bergum PW; Gardell SJ
    J Biol Chem; 1992 Sep; 267(25):17726-31. PubMed ID: 1387641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator.
    Gardell SJ; Duong LT; Diehl RE; York JD; Hare TR; Register RB; Jacobs JW; Dixon RA; Friedman PA
    J Biol Chem; 1989 Oct; 264(30):17947-52. PubMed ID: 2509450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis.
    Mellott MJ; Stabilito II; Holahan MA; Cuca GC; Wang S; Li P; Barrett JS; Lynch JJ; Gardell SJ
    Arterioscler Thromb; 1992 Feb; 12(2):212-21. PubMed ID: 1371932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators.
    Toschi L; Bringmann P; Petri T; Donner P; Schleuning WD
    Eur J Biochem; 1998 Feb; 252(1):108-12. PubMed ID: 9523718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
    Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats.
    Witt W; Baldus B; Bringmann P; Cashion L; Donner P; Schleuning WD
    Blood; 1992 Mar; 79(5):1213-7. PubMed ID: 1536947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vampire bat salivary plasminogen activator evokes minimal bleeding relative to tissue-type plasminogen activator as assessed by a rabbit cuticle bleeding time model.
    Mellott MJ; Ramjit DR; Stabilito II; Hare TR; Senderak ET; Lynch JJ; Gardell SJ
    Thromb Haemost; 1995 Mar; 73(3):478-83. PubMed ID: 7545321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits.
    Gardell SJ; Ramjit DR; Stabilito II; Fujita T; Lynch JJ; Cuca GC; Jain D; Wang SP; Tung JS; Mark GE
    Circulation; 1991 Jul; 84(1):244-53. PubMed ID: 1905593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma.
    Declerck PJ; Lijnen HR; Verstreken M; Moreau H; Collen D
    Blood; 1990 May; 75(9):1794-800. PubMed ID: 1691934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
    Weitz JI
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
    Montoney M; Gardell SJ; Marder VJ
    Circulation; 1995 Mar; 91(5):1540-4. PubMed ID: 7867196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.